Germany
· Delayed Price · Currency is EUR ImmuPharma Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom.
Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas.
The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis.
Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection.
It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC.
ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 6 |
| CEO | Timothy McCarthy |
Contact Details
Address: One Bartholomew Close London, EC1A 7BL United Kingdom | |
| Phone | 44 20 7206 2650 |
| Website | immupharma.co.uk |
Stock Details
| Ticker Symbol | 25I |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy McCarthy | Chief Executive Officer |
| Ashley Clarke | Chief Financial Officer |
| Timothy Franklin | Chief Operating Officer |
| Lisa Baderoon | Head of Investor Relations |